Results 1 to 10 of about 213 (110)
The breakthrough of a limited number of clones while on immune checkpoint inhibitors (ICIs), known as oligoprogression, has been previously described.
Matthew D Galsky +2 more
exaly +3 more sources
AimsOligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen ...
Nina Tunariu +2 more
exaly +3 more sources
Background: While the concept of oligometastatic disease is increasingly recognized as a distinct clinical disease state, the concept of oligoprogression is less well-characterized.
Matthew D Galsky +2 more
exaly +3 more sources
AimTo evaluate the clinical outcomes of metastatic colorectal cancer (mCRC) patients with oligometastases, oligoprogression, or local control of dominant tumors after stereotactic body radiotherapy (SBRT) and establish a nomogram model to predict the ...
Cheng Chen, Xiao-Yuan Chu, Yulu Zhao
exaly +3 more sources
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma [PDF]
Background: A limited degree of progression after a response to treatment is labelled as oligoprogression and is a hot topic of metastatic melanoma (MM) management. Rogue progressive metastases could benefit from local treatment, which could allow the continuation of ongoing systemic therapy, also known as treatment beyond progression (TBP).
Federica de Luca +2 more
exaly +4 more sources
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study
Introduction: The patterns of oligoprogression after first-line immune checkpoint inhibitors (ICIs) for metastatic NSCLC are yet to be well established.
Lauren J Brown
exaly +3 more sources
Stereotactic ablative radiotherapy (SABR) may improve survival in patients with inoperable pulmonary oligometastases. However, the impact of pulmonary oligometastatic status after systemic therapy on SABR outcomes remains unclear.
Chia-Chun Kuo +2 more
exaly +3 more sources
Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy
Background: Oligoprogression is defined as cancer progression of a limited number of metastases under active systemic therapy. The role of metastasis-directed therapy, using stereotactic body radiotherapy (SBRT), is controversial as is the continuation ...
Jonas Willmann +8 more
doaj +4 more sources
IntroductionImmune checkpoint inhibitors (ICIs) have changed the management of non-small cell lung cancer (NSCLC). However, resistance is inevitable.
Yanjun Xu, Hui Li, Yun Fan
doaj +1 more source
Background Oligoprogression is an emerging issue in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Pang-Shuo Perng +10 more
doaj +1 more source

